192
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The Italian Mastocytosis Registry: 6-year experience from a Hospital-Based Registry

, , , , , , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 2713-2723 | Received 11 Apr 2018, Accepted 20 Jul 2018, Published online: 12 Sep 2018

References

  • WHO classification of tumors (2018). http://whobluebooks.iarc.fr/volumes/index_hlt.php.
  • Valent P , HornyHP, EscribanoLet al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res.25(7), 603–625 (2001).
  • Valent P , AkinC, EscribanoLet al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest.37(6), 435–453 (2007).
  • Valent P , AkinC, MetcalfeDD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood129(11), 1420–1427 (2017).
  • Valent P , AkinC, HartmannKet al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res.77(6), 1261–1270 (2017).
  • Hartmann K , EscribanoL, GrattanCet al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergology and Clinical Immunology. J. Allergy Clin. Immunol.137(1), 35–45 (2016).
  • Pardanani A . Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification and management. Am. J. Haematol.90(3), 250–262 (2015).
  • Pieri L , BonadonnaP, ElenaCet al. Clinical presentation and management practice of systemic mastocytosis: survey on 460 Italian patients. Am. J. Haematol.91(7), 692–699 (2016).
  • Rouet A , AoubaA, DamajGet al. Mastocytosis among elderly patients: a multicenter retrospective French study on 53 patients. Medicine (Baltimore)95(24), e3901 (2016).
  • Jawhar M , SchwaabJ, HornyHPet al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur. J. Clin. Invest.46(5), 392–397 (2016).
  • Valent P . Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology Am. Soc. Hematol. Educ. Program2015, 98–105 (2015).
  • Valent P , AkinC, ArockMet al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int. Arch. Allergy Immunol.157(3), 215–225 (2012).
  • Valent P . Mast cell activation syndromes: definition and classification. Allergy68(4), 417–424 (2013).
  • Nagata H1 , WorobecAS, OhCKet al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl Acad. Sci. USA92(23), 10560–10564 (1995).
  • Arock M , SotlarK, AkinCet al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia29(6), 1223–1232 (2015).
  • Pardanani A . Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification and management. Am. J. Haematol.88(7), 612–624 (2013).
  • Sánchez-Muñoz L , MorgadoJM, Álvarez-TwoseIet al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br. J. Haematol.172(1), 56–63 (2016).
  • Kristensen T , VestergaardH, Bindslev-JensenC, M⊘llerMB, Broesby-OlsenS. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am. J. Haematol.89, 493–498 (2014).
  • Cohen SS , SkovboS, VestergaardHet al. Epidemiology of systemic mastocytosis in Denmark. Brit. J. Haematol.166(4), 521–528 (2014).
  • NIH Clinical Research Trials and You (2016). www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries.
  • Méni C , BruneauJ, Georgin-LavialleSet al. Paediatric mastocytosis: a systematic review of 1747 cases. Br. J. Dermatol.172(3), 642–651 (2015).
  • Heide R , van DoornK, MulderPGet al. Serum tryptase and SCORMA (SCORing MAstocytosis) index as disease severity parameters in childhood and adult cutaneous mastocytosis. Clin. Exp. Dermatol.34(4), 462–468 (2009).
  • Zanotti R , BonadonnaP, BonifacioMet al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica96(3), 482–484 (2011).
  • Alvarez-Twose I , ZanottiR, González-de-OlanoDet al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J. Allergy Clin. Immunol.133(2), 520–528 (2014).
  • Pardanani A . How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood121, 3085–3094 (2013).
  • Broesby-Olsen S , DybedalI, GülenTet al. Multidisciplinary management of mastocytosis: Nordic Expert Group Consensus. Acta Derm. Venereol.96(5), 602–612 (2016).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.